截至发稿，诺唯赞市值为79亿元。 （记者 曾健辉） 2024年1至12月份，诺唯赞的营业收入构成为：研究和试验发展占比85.17%，医药制造业占比14.66%， 其他业务占比0.17%。 每经AI快讯，诺唯赞（SH 688105，收盘价：19.75元）12月24日晚间发布公告称，公司于2025年12月24 日收到国寿成达出具的《关于减持计划时间届满暨减持结果的告知函》，国寿成达于2025年9月24日至 2025年12月23日期间，通过集中竞价方式累计减持公司股份约319万股，占公司当前总股本的0.8%。本 次减持计划时间区间已届满。 每经头条（nbdtoutiao）——左手"欠款"右手"豪购"！杨陵江收购"国内酒庄第一股"，1919是否重启上 市？"吹太多牛都实现了，但千亿还没实现，我很着急" ...

格隆汇12月24日丨诺唯赞(688105.SH)公布，公司于2025年12月24日收到国寿成达出具的《关于减持计 划时间届满暨减持结果的告知函》，国寿成达于2025年9月24日至2025年12月23日期间，通过集中竞价 方式累计减持公司股份318.64万股，占公司当前总股本的0.80%。截至本公告披露日，上述减持计划时 间区间已届满。 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-058 南京诺唯赞生物科技股份有限公司 关于股东减持股份计划时间届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688105 证券简称：诺唯赞 公告编号：2025-058 重要内容提示： 股东持股的基本情况 本次减持计划实施前，南京诺唯赞生物科技股份有限公司（以下简称"公司"） 股东国寿成达（上海）健康产业股权投资中心（有限合伙）（以下简称"国寿成 达"）持有公司股份 30,957,960 股，占公司总股本比例为 7.78%。上述股份来源 均为公司首次公开发行股票并上市前取得的股份，且已于 2022 年 11 月 15 日解 除限售并上市流通。 减持计划的实施结果情况 公司于 2025 年 9 月 3 日披露了《关于持股 5%以上股东减持股份计划的公告》 （公告编号：2025-039），国寿成达计划于 2025 年 9 月 24 日至 2025 年 12 月 23 日期间，通过大宗交易及集中竞价的方式减持公司股份合计不超 ...

诺唯赞公告，股东国寿成达原持股3095.8万股，占7.78%。其于2025年9月24日至12月23日拟减持不超 1193.2万股（不超3%）；期间通过集中竞价累计减持318.64万股，占0.8011%，价格区间20.17～24.34 元/股，减持金额6768.17万元。当前持股2777.15万股，占6.9824%，未减874.56万股，减持计划已届 满。 ...

Group 1 - The core business of the company includes research and development of functional proteins and high molecular organic materials, with a focus on biological reagents, in vitro diagnostics, and antibody drug development [2] - As of September 30, the company reported a total revenue of 952 million yuan for the first nine months of 2025, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.6152 million yuan, down 63.57% year-on-year [2] - The company has a total of 9,447 shareholders, which is an increase of 9.90% compared to the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 2 - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3 - On December 23, the company's stock price fell by 1.16%, with a trading volume of 32.5978 million yuan [1] - The financing buy-in amount on December 23 was 5.6547 million yuan, with a net financing buy-in of 512,800 yuan, bringing the total financing and securities balance to 123 million yuan [1] - The company's financing balance accounts for 1.58% of its circulating market value and is at a high level, exceeding the 90th percentile over the past year [1] - On the same day, the company had a short selling amount of 48,000 shares, with a total short selling value of 94,300 yuan, while the short selling balance was 188,600 yuan, which is below the 10th percentile over the past year [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-057 南京诺唯赞生物科技股份有限公司 关于持股5%以上股东权益变动触及1%刻度的提示性公告 国寿成达（上海）健康产业股权投资中心（有限合伙）保证向本公司提供的信息真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688105证券简称：诺唯赞 公告编号：2025-057 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 ■ 3.一致行动人信息 上述信息披露义务人无一致行动人。 二、权益变动触及1%刻度的基本情况 本次权益变动后，国寿成达持有公司股份数量由30,957,960股减少至27,772,168股，占公司总股本的比例 由7.78%减少至6.98%，权益变动触及1%的整数倍，具体情况如下： ■ 注：比例如有尾差，为数据四舍五入所致。 三、其他说明 （一）本次权益变动为公司股东履行已披露的减持股份计划，不触及要约收购。具体内容详见2025年9 月3日公司于上 ...

国寿成达（上海）健康产业股权投资中心（有限合伙）保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | 比例减少☑ | | --- | --- | --- | | 权益变动前合计比例 | 7.78% | | | 权益变动后合计比例 | 6.98% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否☑ | | 是否触发强制要约收购义务 | 是□ | 否☑ | 证券代码：688105 证券简称：诺唯赞 公告编号：2025-057 一、信息披露义务人及其一致行动人的基本信息 南京诺唯赞生物科技股份有限公司 关于持股5%以上股东权益变动触及1%刻度的 提示性公告 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | 投资者及其一致行动 | 5%以上大股东及其一致行动人 ☑其他 | | 人的身份 | □合并口径第一大股东及其一致行动人（仅适用于无控 | | | 股股东、实际控制人） | | | □其他_______ ...

Group 1 - The core point of the article is that Guoshou Chengda has reduced its stake in Nuovizhan (688105.SH) by 3.1858 million shares, which is 0.80% of the company's total share capital [1] - Following this reduction, Guoshou Chengda's shareholding decreased from 30.958 million shares to 27.7722 million shares, representing a change in ownership from 7.78% to 6.98% of the total share capital [1] - The equity change triggered a threshold of 1% integer multiple [1]

Group 1 - CICC is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, with trading resuming on December 18, 2025 [1] - Victory Energy's major shareholder plans to transfer 29.99% of its shares to Qiteng Robotics, with no plans for asset restructuring in the next 12 months [2] - China Metallurgical Group intends to repurchase A-shares worth 1 to 2 billion yuan at a price not exceeding 4.9 yuan per share [3] Group 2 - Boten Co. plans to acquire part of the Yifeng Yunding Fund for 1 yuan, with a commitment to fulfill a 20 million yuan capital contribution [4] - Tongyou Technology has initiated a 50 million yuan accounts receivable factoring business [5] - Gaode Infrared has received approval to issue debt financing tools totaling up to 3 billion yuan [6] Group 3 - Zhengyu Industrial's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] - China CRRC signed contracts totaling approximately 53.31 billion yuan, accounting for 21.6% of its projected 2024 revenue [9] - High Energy Environment's director increased his stake by purchasing 56,100 shares [10] Group 4 - Shantou Technology received approval from the CSRC for a convertible bond issuance [11] - Puyang Co. plans to use up to 900 million yuan of idle funds for entrusted wealth management [12] - Huibai New Materials has been awarded a government subsidy of 3.8 million yuan, with the first installment of 2.12 million yuan already received [13] Group 5 - Jiayuan Technology's shareholders plan to transfer 2.51% of the company's shares through a pricing inquiry [14] - Lingpai Technology's subsidiary terminated a 125 million yuan procurement contract due to market changes [15] - Juguang Technology intends to use up to 200 million yuan of idle funds for cash management [16] Group 6 - Zhongwen Media's subsidiary terminated a 200 million yuan private equity fund subscription due to market changes [17] - Zhifei Biological's modified vaccine for monkeypox has received clinical trial acceptance [19] - GeKowei's subsidiary received a government subsidy of 60 million yuan, accounting for 32.12% of the company's audited net profit [20] Group 7 - Wantai Biological's application for a clinical trial of a respiratory syncytial virus vaccine has been accepted [21] - Haitai Technology plans to increase capital in its Thai joint venture from 500,000 to 3 million Thai baht [22] - Shanghai Airport signed contracts for the transfer of duty-free store operating rights [23] Group 8 - Del Shares received approval to issue shares for the acquisition of 100% of Aizhuo Intelligent [24] - Novozymes' products have obtained EU CE IVDR certification [25] - Shibai Testing's chairman's assistant plans to increase shareholding by 8 to 12 million yuan [26] Group 9 - Huitian New Materials plans to invest approximately 97.68 million yuan in a lithium battery anode glue project [27] - Pudong Construction's subsidiaries won contracts totaling 1.649 billion yuan [29] - Acolyte's subsidiary has entered trial production for a special high-temperature resistant resin project [30] Group 10 - Pingzhi Information's subsidiary signed a 38.25 million yuan computing power service contract [31] - Tianma Technology is required to pay 5.3625 million yuan in taxes and penalties [32] - Yahon Pharmaceutical's clinical trial application for GLX002 has been approved [34]

一、获证产品的基本情况 证券代码：688105 证券简称：诺唯赞 公告编号：2025-056 南京诺唯赞生物科技股份有限公司 关于自愿披露公司产品取得欧盟CE IVDR认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）六项呼吸道病原体 核酸检测试剂盒于近日取得欧盟 CE IVDR 认证，可在欧盟国家和认可欧盟 CE 认 证的国家进行销售，具体情况如下： （一）认证信息 | 名称 | 分类 | 有效期至 | | 证书编号 | 预期用途 | 参考图示 | | --- | --- | --- | --- | --- | --- | --- | | Logilet Respiratory | | 2030 | 年 | EU-QMS-FI 01219-8000 | 用于辅助诊断呼吸道 合胞病毒、甲型流感病 | | | Pathogen Panel | Class | 12 月 | 9 日 | 33-2025 | 毒、乙型流感病毒、严 | | | 六项呼吸道病 | B | 2 ...